FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB	APPR	OVAI

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address			2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [BRTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
ALSTODT LANCE			Bierresiani Francisco, mei	X	Director	X	10% Owner		
(Last) (First) (Middle)		(Middle)			Officer (give title below)		Other (specify below)		
(Last) (First) (Middle) C/O BIORESTORATIVE THERAPIES, INC. 40 MARCUS DRIVE, SUITE 1		, ,	3. Date of Earliest Transaction (Month/Day/Year) 03/18/2021		President, CEO, COB				
(Street) MELVILLE	•		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	ndividual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)			,		. •		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acc Disposed Of (D)			Securities	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	3 and 4)		(11311. 4)
Common Stock	03/18/2021		A		586,958,987	A	(1)	605,670,653(2)	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ite	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Stock Option	\$0.0119	03/18/2021		A		1,173,917,974		(3)	03/18/2031	Common Stock	1,173,917,974	\$0	1,173,917,974	D	

Explanation of Responses:

- 1. Shares received pursuant to a restricted stock unit grant. Vests in three nearly equal annual installments beginning March 18, 2022.
- 2. Includes 586,958,987 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 195,652,996 shares on each of March 18, 2022 and March 18, 2023 and 195,652,995 shares on March 18, 2024 and March 18, 2023 and 195,652,995 shares on March 18, 2024 and Ma
- 3. Such shares vest to the extent of 586,958,987 shares on the date of grant, 293,479,494 shares on March 18, 2022 and 293,479,493 shares on March 18, 2023.

/s/ Lance Alstodt

03/19/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.